Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma
BNL Finance’s top calls involve RAD, AMZN, BMY, FNMA stock, BAC stock, XPO, FB, and UAA among others. However, stock performance is not the only factor.
Bristol-Myers Squibb Co (NYSE:BMY) and Merck & Co., Inc. (NYSE:MRK) prove that trial design and strategy matters. This is something Kite Pharma Inc (NASDAQ:KITE) and Juno Therapeutics Inc (NASDAQ:JUNO) investors must notice.
Gilead stock price multiple coupled with GILD’s corporate outlook make it a great acquisition target for Pfizer, Merck, or even Johnson & Johnson.
Acadia Pharmaceuticals just told investors that a major marketing partnership for Nuplazid or acquisition is not going to happen, and ACAD stock owners will be better off because of it.